| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/1999 | CA2307891A1 Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 05/06/1999 | CA2307890A1 Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 05/06/1999 | CA2307889A1 Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
| 05/06/1999 | CA2307828A1 6,11-bridged erythromycin derivatives |
| 05/06/1999 | CA2307790A1 Antihistamine/decongestant regimens for treating rhinitis |
| 05/06/1999 | CA2307748A1 Aminomethyl-benzo[a]quinolizidine derivatives, preparation and therapeutic applications for neurodegenrative diseases |
| 05/06/1999 | CA2307661A1 Cyclopentene derivatives useful as antagonists of the motilin receptor |
| 05/06/1999 | CA2307595A1 Synthesis of swainsonine salts |
| 05/06/1999 | CA2307320A1 148 human secreted proteins |
| 05/06/1999 | CA2307163A1 Process for stereoselective synthesis of prostacyclin derivatives |
| 05/06/1999 | CA2307030A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 05/06/1999 | CA2306878A1 Bis-quaternary ammonium derivatives as neuromuscular relaxants |
| 05/06/1999 | CA2306817A1 Treatment of schizophrenia with ampakines and neuroleptics |
| 05/06/1999 | CA2306379A1 Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye |
| 05/06/1999 | CA2306082A1 Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors |
| 05/06/1999 | CA2305349A1 Methods and pharmaceutical compositions for the closure of retinal breaks |
| 05/06/1999 | CA2305293A1 Administration of active agents, including 5-ht receptor agonists and antagonists, to treat premature ejaculation |
| 05/06/1999 | CA2305258A1 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
| 05/06/1999 | CA2304815A1 .beta.-d glucan topical composition |
| 05/06/1999 | CA2302417A1 Adenosine a3 receptor antagonists |
| 05/05/1999 | CN1216064A Synthetic HIV genes |
| 05/05/1999 | CN1216063A IL-6 mutein |
| 05/05/1999 | CN1216047A Antifungic and antibaterial peptide |
| 05/05/1999 | CN1216046A 3-[(1,2,3,4-tetrahydroisoquinoline-2-yl) methyl]-8-azabicyclo [3.2.1] octane derivs, their preparation and their use in therapeutics |
| 05/05/1999 | CN1216044A Non-steroidal polycyclic ring sulphamate derivs, their preparation and their use as oestrone sulphatase inhibitors |
| 05/05/1999 | CN1216043A Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors |
| 05/05/1999 | CN1216042A Carboxylic acid derivs, their production and use |
| 05/05/1999 | CN1216041A Carboxylic acid derivs, their production and use |
| 05/05/1999 | CN1216036A Novel tetralone or benzopyranone derivs and process for producing same |
| 05/05/1999 | CN1216035A Method for preparing substd. anthraguinone and application to preparation of rheins |
| 05/05/1999 | CN1215996A Indications for use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses |
| 05/05/1999 | CN1215994A Rnase L activators and antisense oligonucleotides effective to treat RSV infections |
| 05/05/1999 | CN1215993A Pharmaceutical formulations |
| 05/05/1999 | CN1215992A Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| 05/05/1999 | CN1215991A Enteric-coated pharmaceutical compositions of mycophenolate |
| 05/05/1999 | CN1215990A IL-8 receptor antagonists |
| 05/05/1999 | CN1215989A Dosage form of ibuprofen |
| 05/05/1999 | CN1215988A Ophthalmic compound with extended dwell time on eye |
| 05/05/1999 | CN1215725A Triterpene derivatives and endothelin-receptor antagonists containing the same |
| 05/05/1999 | CN1215724A Novel compounds |
| 05/05/1999 | CN1215592A Oral calcium L-threonate liquid |
| 05/05/1999 | CN1215591A Chroman derivative-containing ophthalmic solution |
| 05/05/1999 | CN1215590A Albendazole suspension for expelling and controlling parasite in livestock, and preparing process thereof |
| 05/05/1999 | CN1043278C Process and apparatus for etching semiconductor wafers |
| 05/05/1999 | CN1043231C Monohydrate of (E)-alpha-deoxy-alpha-(fluoro-methylene) cytidine |
| 05/05/1999 | CN1043230C Serotoninergic ergoline derivs. |
| 05/05/1999 | CN1043227C Ceramide, preparation and application in comsetic and dermatological pharmaceutical of same |
| 05/04/1999 | US5900488 Method for treating mycosis using imidazolylacetonitrile derivatives |
| 05/04/1999 | US5900486 Fungicides |
| 05/04/1999 | US5900475 Modified polyallylamine; anticholesterol agent |
| 05/04/1999 | US5900436 Therapy for lipid metabolism disorders |
| 05/04/1999 | US5900435 Liquid food |
| 05/04/1999 | US5900434 Method for inhibiting the production of interleukin-1 or tumor necrosis factor-α by administering acanthoic acid |
| 05/04/1999 | US5900433 Use of a congener of an endothelium-derived bioactive composition of matter, which comprises administering said congener percutaneously to a site proximately adjacent the exterior of a coronary blood vessel at a therapeutically |
| 05/04/1999 | US5900432 Therapeutic N-(4-benzoyl-2-methyl-phenyl)-3,3,3-trifluoro-2-hydroxy-2-methyl-propanamides |
| 05/04/1999 | US5900431 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections |
| 05/04/1999 | US5900430 Cytokine inhibitors |
| 05/04/1999 | US5900429 Treating breast cancer in mammals by administering taxol or cisplatin to reduce tumor or cancer, then administering 2-methoxycarbonylaminobenzimidazole or pharmaceutical addition salts; anticarcinogenic/antitumor agents |
| 05/04/1999 | US5900428 Pharmacological use of AII-receptor antagonists |
| 05/04/1999 | US5900424 Omeprazole magnesium salt form |
| 05/04/1999 | US5900421 Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine |
| 05/04/1999 | US5900420 Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| 05/04/1999 | US5900419 Solution or suspension of camptothecin derivative in n-methyl-2-pyrrolidone, pharmaceutically acceptable acid, polyethylene glycol, lower alcohol or benzyl alcohol |
| 05/04/1999 | US5900418 Administering acetylcholine estease activator |
| 05/04/1999 | US5900416 Aqueous caffeine dosage forms |
| 05/04/1999 | US5900415 Dietetic and cardiovascular disorders |
| 05/04/1999 | US5900414 Topical applying to eye |
| 05/04/1999 | US5900413 Administering with amoxicillin |
| 05/04/1999 | US5900412 Percutaneous/transdermal delivery of ASA and antithrombotic therapies based thereon |
| 05/04/1999 | US5900411 Forscarnet |
| 05/04/1999 | US5900409 Cerebration improver |
| 05/04/1999 | US5900408 Sustained release |
| 05/04/1999 | US5900407 Method of treating dry eye disease with uridine triphosphates and related compounds |
| 05/04/1999 | US5900406 Use of antibiotics of the type 2-deoxystreptamine substituted with aminosugars to inhibit growth of microorganisms containing group I introns |
| 05/04/1999 | US5900360 Screening protein stabilizing agents (not congo red) by incubating cell containing conformationally defective protein, determining effective concentration to improve phenotype; treatment of cystic fibrosis, scrapie |
| 05/04/1999 | US5900257 Cosmetic/pharmaceutical compositions comprising lanthanide manganese, tin and/or yttrium salts as substance P antagonists |
| 05/04/1999 | US5900255 Material for prevention and treatment of osteoporosis |
| 05/04/1999 | US5900252 Multidose minitablet drug cores surrounded by a first polymeric membrane soluble at ph above 5.5 and an outer insoluble membrane which is permeable to gastric fluids, for timed release in ileum or colon |
| 05/04/1999 | US5900250 Monoglyceride/lactate ester permeation enhancer for oxybutnin |
| 05/04/1999 | US5900247 Mucoadhesive pharmaceutical composition for the controlled release of active principles |
| 05/04/1999 | US5900233 Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome |
| 05/04/1999 | US5900231 Cosmetic and/or dermatological skin treatment |
| 05/04/1999 | CA2184604C Bicyclic carbamates |
| 05/04/1999 | CA2180424C Drugs, vaccines and hormones in polylactide coated microspheres |
| 05/04/1999 | CA2163706C Amino acid derivatives of paclitaxel |
| 05/04/1999 | CA2137001C Lipids for epidermal moisturization and repair of barrier function |
| 05/04/1999 | CA2078129C O6-benzylated guanine, guanosine and 2'- deoxyguanosine compounds possessing o6-alkylguanine-dna alkyltransferase depleting activity |
| 05/04/1999 | CA2074641C Method of treating ocular inflammation |
| 05/04/1999 | CA2063689C Ibuprofen lysinate pharmaceutical formulation |
| 05/04/1999 | CA2058619C Process for the preparation of substituted isoflavone derivatives |
| 05/04/1999 | CA1340530C Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics |
| 05/04/1999 | CA1340529C Pediatric ibuprofen compositions |
| 05/04/1999 | CA1340527C Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities |
| 05/03/1999 | CA2252733A1 Sulfonamide-substituted benzopyran derivatives, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them |
| 04/30/1999 | CA2249879A1 Synthetic core 2-like branched structures containing galnac-lewisx and neu5ac.alpha.2-3gal.beta.1-3galnac sequences as novel ligands for selectins |
| 04/30/1999 | CA2249056A1 Lacc |
| 04/30/1999 | CA2248996A1 Novel ornithine carbamoyltransferase |
| 04/30/1999 | CA2237419A1 An aglucone isoflavone enriched vegetable protein extract and isolate and process for producing |
| 04/30/1999 | CA2219867A1 The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
| 04/29/1999 | WO1999020791A1 Method for suppressing multiple drug resistance in cancer cells |